Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
Rani Therapeutics (Nasdaq: RANI) will present preclinical data on oral semaglutide (RT-116) delivered via the RaniPill® capsule at ObesityWeek® 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rani Therapeutics (Nasdaq: RANI) will present preclinical data on oral semaglutide (RT-116) delivered via the RaniPill® capsule at ObesityWeek® 2025.
The abstract reports that oral semaglutide in dogs was bioequivalent to subcutaneous injections and produced similar weight loss. The poster (No. 647) will be presented by Kyle Horlen, DVM, VP of Nonclinical Development, on November 6, 2025, 2:30–3:30 pm ET at the Georgia World Congress Center, Exhibit Hall A1; the meeting is Nov 4–7, 2025 and includes virtual participation.
Details
News Market Reaction – RANI
On Oct 30, the day this news came out, RANI closed 12.65% below the previous close.
Data tracked by StockTitan Argus for the Oct 30 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule, the company’s oral delivery platform, at ObesityWeek® 2025 taking place both virtually and in-person on November 4-7, 2025 in Atlanta, Georgia.
Details of the presentation are as follows:
Abstract Title: Oral Semaglutide (RT-116) in Dogs is Bioequivalent to SC Injections and Elicits Similar Weight Loss
Session Type: Poster Session
Poster Number: 647
Location: Georgia World Congress Center, Exhibit Hall A1
Session Date & Time: November 6, 2025 from 2:30 pm – 3:30 pm E.T.
Presenting Author: Kyle Horlen, DVM, VP of Nonclinical Development
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.